Patents Assigned to NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
-
Publication number: 20210101882Abstract: A class of fluorine-substituted indazole compounds and uses thereof, further to pharmaceutical compositions containing these compounds. The compounds and pharmaceutical compositions of the invention can be used as soluble guanylate cyclase simulators.Type: ApplicationFiled: April 10, 2018Publication date: April 8, 2021Applicants: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Yinglin ZUO, Xiaojun WANG, Chuanwen YANG, Jiancheng WANG, Shengtian CAO, Fangyuan WU, Yingjun ZHANG, Siegfried GOLDMANN
-
Publication number: 20200283454Abstract: Disclosed are a compound as shown in formula (I) as an influenza virus replication inhibitor and a preparation method therefor, a pharmaceutical composition comprising the compound and the use of the compound and pharmaceutical composition thereof in the treatment of influenza.Type: ApplicationFiled: September 18, 2018Publication date: September 10, 2020Applicants: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Changhua TANG, Qingyun REN, Huichao LUO, Junjun YIN, Kai YI, Yibo LEI, Yejun WANG, Yingjun ZHANG
-
Publication number: 20200276196Abstract: A substituted pyrimidine piperazine compound and uses thereof, and a pharmaceutical composition containing the compound and uses thereof. Wherein the compound has Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The substituted pyrimidine piperazine compound and the pharmaceutical composition containing the compound can be used to inhibit 5-hydroxytryptamine reuptake and/or activate the 5-HT1A receptors. Also, a method of preparing such compounds and pharmaceutical compositions, and uses thereof in the treatment of central nervous system dysfunction.Type: ApplicationFiled: September 21, 2018Publication date: September 3, 2020Applicants: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Chuanfei JIN, Wenhe ZHONG, Haiping LIANG, Yingjun ZHANG
-
Patent number: 10683297Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: GrantFiled: November 10, 2018Date of Patent: June 16, 2020Assignees: CALITOR SCIENCES, LLC, NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Ning Xi, Minxiong Li, Ju Peng, Xiaobo Li, Tao Zhang, Haiyang Hu, Wuhong Chen, Changlin Bai, Donghua Ke, Peng Chen
-
Publication number: 20200157054Abstract: A method for preparing a pyrimidone compound and an important intermediate in which raw materials of the preparation method are cheap, the reaction condition of preparation method is mild, the preparation method is simple to operate, and is safe and controllable, has high total yield, and thus is suitable for industrial production.Type: ApplicationFiled: July 3, 2018Publication date: May 21, 2020Applicant: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Runfeng LIN, Xiaojun WANG, Jihua LIN, Liang CHEN, Yingjun ZHANG, Jiancun ZHANG
-
Patent number: 10654797Abstract: Provided herein are crystalline forms of (((((1r, 3R, 5S, 7r)-3, 5-dimethyladamantan-1-yl)carbamoyl) oxy) methyl benzoate (Compound (I)): Also provided are compositions comprising the crystalline forms of Compound (I), processes of manufacture and methods of using the crystalline forms of Compound (I).Type: GrantFiled: November 2, 2017Date of Patent: May 19, 2020Assignee: North & South Brother Pharmacy Investment Company LimitedInventors: Huiqing Ye, Jinchao Xu, Bifei He, Guangyuan Liu, Yuping Fan, Zhongqing Wang, Zhonghua Luo
-
Patent number: 10647693Abstract: The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the manufacture of medicaments for treating of influenza.Type: GrantFiled: August 29, 2017Date of Patent: May 12, 2020Assignee: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Changhua Tang, Qingyun Ren, Junjun Yin, Kai Yi, Yingjun Zhang
-
Patent number: 10647682Abstract: Provided are salts of 2,6-dimethylpyrimidone derivatives and uses thereof. Also provided are pharmaceutical compositions containing the salts.Type: GrantFiled: July 19, 2017Date of Patent: May 12, 2020Assignee: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Runfeng Lin, Liang Chen, Xiaojun Wang, Yingjun Zhang, Jiancun Zhang
-
Patent number: 10632163Abstract: The present disclosure pertains to the field of processing fresh traditional Chinese medicinal materials, and particularly relates to a method of preparing a fresh Ophiocordyceps sinensis product. The fresh Ophiocordyceps sinensis product may be prepared by the following steps: 1) stripping off mud from a fresh Ophiocordyceps sinensis; 2) brushing with flowing water; 3) cleaning ultrasonically; 4) humidifying the cleaned fresh Ophiocordyceps sinensis with atomized water for 15 to 20 minutes; 5) packaging the humidified fresh Ophiocordyceps sinensis by sealing it in a tube charged with a modified-atmosphere; and 6) storing the tube at a low temperature; wherein step 1) to step 4) are carried out at a temperature from 3 to 15° C. The present disclosure also relates to a fresh Ophiocordyceps sinensis product prepared by the above method.Type: GrantFiled: December 29, 2017Date of Patent: April 28, 2020Assignee: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Zhengming Qian, Zhong Ai, Wenjia Li, Guangrong Li, Wenxiang Zhang, Xiangqin Xu, Xinfa Tang
-
Publication number: 20200121690Abstract: A salt of a substituted urea derivative of formula (I) and use thereof in the pharmaceutical field. Also, a pharmaceutical composition containing the salt or a combination thereof, and use of the salt or the pharmaceutical composition in the manufacture of a medicament for treating, remitting or preventing a disorder related to tyrosine kinase activity.Type: ApplicationFiled: July 11, 2018Publication date: April 23, 2020Applicant: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Liang CHEN, Chengxi LI, Bing LIU, Yingjun ZHANG, Changchung CHENG
-
Publication number: 20200115381Abstract: A dihydropyrimidine compound and a pharmaceutical application thereof, especially the application used for treating and preventing HBV diseases. Specifically, a compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also, use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicine, especially for treating and preventing HBV diseases.Type: ApplicationFiled: June 25, 2018Publication date: April 16, 2020Applicant: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Qingyun REN, Xinchang LIU, Jianzhou HUANG, Yingjun ZHANG, Siegfried GOLDMANN
-
Publication number: 20200113879Abstract: A fused tricyclic compound and use thereof as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. Specifically, a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variate is as defined in specification. The compound also includes a Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B.Type: ApplicationFiled: June 2, 2018Publication date: April 16, 2020Applicants: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Xinchang LIU, Qingyun REN, Jianzhou HUANG, Zhimin XIONG, Jinfeng XIONG, You LI, Yang LIU, Zhifu ZOU, Guanghua YAN, Siegfried GOLDMANN, Yingjun ZHANG
-
Publication number: 20200085822Abstract: The invention provides a class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.Type: ApplicationFiled: December 14, 2017Publication date: March 19, 2020Applicants: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Changhua TANG, Qingyun REN, Junjun YIN, Kai YI, Yibo LEI, Yejun WANG, Yingjun ZHANG
-
Publication number: 20200079721Abstract: The present invention relates to a sacubitril intermediate and a preparation method thereof. The sacubitril intermediate disclosed herein can be prepared by a deprotection reaction of a compound. In addition, the intermediate can be used as a raw material to synthesize sacubitril.Type: ApplicationFiled: November 9, 2019Publication date: March 12, 2020Applicant: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Lei CHEN, Guodong SUN, Xiaodong HAN, Shun LI, Jiebin ZENG, Zhongqing WANG, Zhonghua LUO
-
Patent number: 10562910Abstract: A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the use of the compound for the treatment of disease and/or condition mediated by FXR are described. And a pharmaceutical composition containing the compound disclosed herein and a method of treatment of disease and/or condition mediated by FXR comprising administering the compound or the pharmaceutical composition thereof are also described.Type: GrantFiled: August 2, 2017Date of Patent: February 18, 2020Assignee: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Xiaojun Wang, Xinye Yang, Junwen Wu, Shaohui Xiong, Shengqiang Pan, Shengtian Cao, Yingjun Zhang
-
Patent number: 10555930Abstract: This present invention relates to a complex of a glucopyranosyl derivative and L-pyroglutamic acid as a sodium dependent glucose cotransporter (SGLT) inhibitor, and preparation processes thereof, and a pharmaceutical composition containing the complex, and their uses in the manufacture of a medicament for treating diabetes and/or diabetes-related diseases.Type: GrantFiled: November 28, 2016Date of Patent: February 11, 2020Assignee: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Pengcho Tang, Zheng Gu, Wuyong Wu, Zongyuan Zhang, Panpan Kang, Tong Qu
-
Patent number: 10537524Abstract: The present invention provided an apixaban solid composition and a preparation method thereof. The method comprises granulating apixaban by wet granulation, wherein the apixaban has a particle size D90 more than 89 ?m.Type: GrantFiled: January 11, 2017Date of Patent: January 21, 2020Assignee: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Qibiao Huang, Xin Huang, Fangfang Huang, Jinsong You, Feng Zhao
-
Patent number: 10501444Abstract: The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.Type: GrantFiled: August 15, 2017Date of Patent: December 10, 2019Assignees: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Qingyun Ren, Changhua Tang, Junjun Yin, Kai Yi, Yingjun Zhang
-
Patent number: 10494364Abstract: The invention relates to capthepsin K inhibitors and uses thereof, specifically relates to a class of compounds having the formula (I) which are used for treating or preventing cathepsin dependent diseases or conditions, specifically, wherein the cathepsin is capthepsin K. The compounds and compositions thereof can be used as bone resorption inhibitors for the treatment of associated diseases.Type: GrantFiled: August 26, 2016Date of Patent: December 3, 2019Assignees: SUNSHIN LAKE PHARMA CO., LTD, NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Xiaojun Wang, Pingjian Zhou, Chuanwen Yang, Changwei Huang, Shaohui Xiong, Yingjun Zhang, Jiancun Zhang
-
Publication number: 20190352311Abstract: The present invention relates to a thienopyrimidine derivative and use thereof in medicine, and also to a pharmaceutical composition containing the compound. The compound or pharmaceutical composition is used for inhibiting acetyl-CoA carboxylase (ACC). The present invention also relates to a method of preparing such compound and pharmaceutical composition, as well as their use in the treatment or prevention of diseases regulated by acetyl-CoA carboxylase in mammals, especially in humans.Type: ApplicationFiled: January 22, 2018Publication date: November 21, 2019Applicants: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Wanjun TANG, Xinye YANG, Zheng GU, Chenlu LI, Zongyuan ZHANG, Zhifu WAN, Xiaojun WANG, Yingjun ZHANG